Shanghai Fosun Pharmaceutical said it will work with German partner BioNTech to develop a new vaccine targeting the omicron variant of COVID-19, but it may take three to four months to win regulatory approval.
Caixin
Fosun and BioNTech to develop vaccine targeting omicron
Many drugmakers expect efficacy of existing jabs lower against new variant
Fosun is the exclusive partner of BioNTech for marketing the co-developed mRNA vaccine in greater China, which includes Hong Kong, Macao and Taiwan. © Reuters
Read Next
Latest on Caixin
